Well Told Grants

Grants / Department of Health and Human Services / Food and Drug Administration

Evaluating the Cutaneous Pharmacokinetics of Topical Drug Products Using Pharmacokinetic Tomography (U01 Clinical Trial Required)

Forecast Forecast, no dates yet Opportunity FOR-FD-24-004

Food and Drug Administration plans to offer grants of up to $250,000 (at least $250,000) to any type of organization. It expects to make one award. It is a forecast, and no dates have been set yet.

From the official notice on Grants.gov, last changed November 24, 2023. Checked October 31, 2026.

Key dates

Forecast postedNovember 24, 2023

Who can apply

This opportunity is open to any type of organization.

Applicant organizations may submit more than one application, provided that each application is scientifically distinct. The FDA will not accept duplicate or highly overlapping applications under review at the same time per 2.3.7.4 Submission of Resubmission Application. This means that the NIH or FDA will not accept:•A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.•A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.•An application that has substantial overlap with another application pending appeal of initial peer review (see 2.3.9.4 Similar, Essentially Identical, or Identical Applications).

More grants for nonprofits, colleges and universities, state and local governments, tribes, small businesses, businesses, individuals.

Is this a realistic fit?

What the grant funds

The purpose of this funding opportunity is to support the research and development necessary to advance non-invasive (e.g., quantitative tomography-based) technologies, including the development of apparatus, methods, study designs, and methods of data analysis, to characterize and compare the rate and extent to which a topically applied drug becomes available at or near a site of action within the skin in vivo. The expectation is that the funded work will produce an accurate, sensitive and reproducible approach that rapidly measures the (relative) amount of drug present in the skin at a series of depths below the skin surface, which can be utilized to monitor the cutaneous pharmacokinetics (PK) of the drug at selected depths (e.g., in the epidermis) by repeated, serial measurements over time. The intent is to support the eventual development of an alternative, scientifically valid, in vivo cutaneous PK-based approach that can be used to efficiently demonstrate the bioequivalence (BE) of topical products.

Category: Agriculture, Consumer Protection, Food and Nutrition.

How to apply

  1. Read the full notice and attachments on Grants.gov. The notice is the official source for deadlines and requirements.
  2. Make sure your organization has an active SAM.gov registration and Unique Entity ID; registration can take several weeks.
  3. Register on Grants.gov and submit through Workspace before the deadline and time given in the notice. Our application guide walks through each step.

Questions go to Terrin Brown, Grantor, terrin.brown@fda.hhs.gov, 2403387494.

Open the official notice

Questions people ask

Who can apply for Evaluating the Cutaneous Pharmacokinetics of Topical Drug Products Using Pharmacokinetic Tomography (U01 Clinical Trial Required)?

Food and Drug Administration accepts applications from any type of organization. The notice adds further conditions, so read its eligibility section.

What is the deadline for Evaluating the Cutaneous Pharmacokinetics of Topical Drug Products Using Pharmacokinetic Tomography (U01 Clinical Trial Required)?

Forecast, no dates yet. Confirm the date and time in the official notice on Grants.gov.

How much funding is available?

Awards of up to $250,000 each.

Similar open grants